Valeant Pharmaceuticals reported quarterly earnings and revenue that fell short of analysts' expectations on Tuesday, but stood by its full-year forecast as it tries to restore investor confidence after facing a storm of criticism over its business practices.
Shares of Valeant gained more than 25 percent on Tuesday.
CEO Joseph Papa told CNBC that Tuesday's price action reflects increased confidence in the company as it stabilizes and returns to growth. He added that he doesn't agree with speculations that Valeant may have to accept lower prices when it sells off non-core assets.
"These assets we're considering to be sold are not going to be in a fire sale. They have real value to potential purchaser," Papa said. He added that he is "very confident" that Valeant will get "fair market value" for these assets.
The Canadian drugmaker in the past year has faced intense political and investor scrutiny for its steep drug price increases and unorthodox use of a specialty pharmacy.
Valeant, which has about $30.77 billion in debt, also had to appease creditors after missing deadlines for filing financial reports, triggering default notices.
The company posted second-quarter earnings of $1.40 per share on $2.42 billion in revenue.
Analysts had expected the company to post earnings of $1.48 per share on $2.46 billion in revenue, according to a Thomson Reuters consensus estimate.